---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-001066"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:28:39.786821+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CNS Pharmaceuticals appoints Steve O'Loughlin as CFO; current CFO Downs moves to SVP Finance

## Summary
- Steve O'Loughlin appointed CFO effective March 2, 2026; base salary $450,000, target bonus 40% of base.
- O'Loughlin receives initial RSU grant of 9,500 shares; 25% vest at 6 months, 25% at 12 months, 50% quarterly thereafter.
- Current CFO Christopher Downs resigns as CFO, becomes SVP - Finance effective March 2; base salary $350,000, target bonus 30%.
- Both employment agreements include 6-month severance (base salary) for termination without cause or for good reason.

## SEC filing metadata
- accession: 0001683168-26-001066
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316826001066/0001683168-26-001066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316826001066/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-001066
- JSON: https://secwatch.observer/filing/0001683168-26-001066.json
- Plain text: https://secwatch.observer/filing/0001683168-26-001066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.